GEG vs IMA Comparison

Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. The Group conducts its operations through two business segments: Alternative Credit and Real Estate. Key revenue comes from the Real Estate segment, which includes a full-service, end-to-end real estate platform combining investment expertise and turnkey execution capabilities for the IOS sector. The Alternative Credit segment focuses on income generation and capital preservation by investing in debt and income-generating securities, direct lending, CLOs, and specialty finance businesses, including factoring, asset-based lending, and healthcare.

ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.